Monika Lindemann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/817398/publications.pdf

Version: 2024-02-01

132 papers

2,688 citations

218677 26 h-index 223800 46 g-index

137 all docs

137 docs citations

times ranked

137

5005 citing authors

#	Article	IF	CITATIONS
1	SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. Journal of Clinical Virology, 2020, 128, 104437.	3.1	307
2	Functional capacities of human IgM memory B cells in early inflammatory responses and secondary germinal center reactions. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E546-55.	7.1	179
3	CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis. Journal of Neuroimmunology, 2006, 180, 178-184.	2.3	128
4	Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leukemia and Lymphoma, 2006, 47, 1570-1582.	1.3	108
5	Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors. Blood, 2003, 102, 1131-1137.	1.4	104
6	Impact of localized radiotherapy on blood immune cells counts and function in humans. Radiotherapy and Oncology, 1999, 50, 199-204.	0.6	103
7	Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2–Specific IgG. Emerging Infectious Diseases, 2021, 27, 122-129.	4.3	90
8	Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2–Specific IgG. Emerging Infectious Diseases, 2021, 27, 122-129.	4.3	90
9	The G protein Î ² 3 subunit 825T allele is a genetic marker for enhanced T cell response. FEBS Letters, 2001, 495, 82-86.	2.8	86
10	Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency. Cancer Research, 2016, 76, 4347-4358.	0.9	63
11	Humoral and Cellular Vaccination Responses against SARS-CoV-2 in Hematopoietic Stem Cell Transplant Recipients. Vaccines, 2021, 9, 1075.	4.4	51
12	Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine. Vaccine, 2014, 32, 5077-5082.	3.8	49
13	Genetic, immunological and clinical risk factors for biliary strictures following liver transplantation. Liver International, 2012, 32, 1253-1261.	3.9	48
14	ELISpot: a new tool for the detection of nickel sensitization. Clinical and Experimental Allergy, 2003, 33, 992-998.	2.9	45
15	Detection of chromium allergy by cellularin vitromethods. Clinical and Experimental Allergy, 2008, 38, 1468-1475.	2.9	36
16	Transfer of humoral and cellular hepatitis B immunity by allogeneic hematopoietic cell transplantation. Transplantation, 2003, 75, 833-838.	1.0	35
17	Donor-Specific Anti-HLA Antibodies and Endothelial C4d Deposition—Association With Chronic Liver Allograft Failure. Transplantation, 2015, 99, 1869-1875.	1.0	35
18	T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients. Journal of Clinical Virology, 2018, 105, 91-96.	3.1	35

#	Article	IF	CITATIONS
19	A NEW RESTRICTION FRAGMENT LENGTH POLYMORPHISM OF THE HUMAN TNF-B GENE DETECTED BY Asp HI DIGEST. International Journal of Immunogenetics, 1992, 19, 425-430.	1.2	32
20	Role of G Protein \hat{I}^2 3 Subunit C825T and HLA Class II Polymorphisms in the Immune Response after HBV Vaccination. Virology, 2002, 297, 245-252.	2.4	32
21	ELISpot assay as a sensitive tool to detect cellular immunity following influenza vaccination in kidney transplant recipients. Clinical Immunology, 2006, 120, 342-348.	3.2	32
22	Second German consensus on immunogenetic donor search for allotransplantation of hematopoietic stem cells. Annals of Hematology, 2001, 80, 706-714.	1.8	31
23	Adoptive Immune Transfer of Hepatitis B Virus Specific Immunity From Immunized Living Liver Donors to Liver Recipients. Transplantation, 2009, 87, 103-111.	1.0	30
24	Clinical validation of a novel enzyme-linked immunosorbent spot assay-based <i>inÂvitro </i> diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study. Transplant International, 2018, 31, 436-450.	1.6	30
25	Cellular and humoral immune response to a third generation hepatitis B vaccine. Journal of Viral Hepatitis, 2007, 14, 592-598.	2.0	29
26	Toll-like Receptors in Regulatory T Cells of Patients With Head and Neck Cancer <alt-title>TLRs in T-reg Cells of HNSCC Patients</alt-title> . JAMA Otolaryngology, 2010, 136, 1253.	1.2	29
27	Cytokines and sudden infant death. International Journal of Legal Medicine, 2012, 126, 279-284.	2.2	28
28	Systematic memory B cell archiving and random display shape the human splenic marginal zone throughout life. Journal of Experimental Medicine, 2021, 218, .	8.5	27
29	Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. Haematologica, 2021, 106, 363-374.	3. 5	26
30	Diagnosis of tuberculosis infection in patients awaiting liver transplantation. Human Immunology, 2009, 70, 24-28.	2.4	24
31	Impaired lymphocyte function in patients with hepatic malignancies after selective internal radiotherapy. Cancer Immunology, Immunotherapy, 2018, 67, 843-853.	4.2	23
32	Prevalence of latent tuberculosis infection in German radiologists. Journal of Hospital Infection, 2008, 69, 69-76.	2.9	22
33	Cytomegalovirus induces apoptosis in acute leukemia cells as a virus-versus-leukemia function. Leukemia and Lymphoma, 2015, 56, 3189-3197.	1.3	22
34	Humoral and Cellular Responses to a Single Dose of Fendrix in Renal Transplant Recipients with Nonâ€response to Previous Hepatitis B Vaccination. Scandinavian Journal of Immunology, 2017, 85, 51-57.	2.7	22
35	Expression of NTRK1/TrkA affects immunogenicity of neuroblastoma cells. International Journal of Cancer, 2013, 133, 908-919.	5.1	20
36	Granzyme B producing B-cells in renal transplant patients. Clinical Immunology, 2017, 184, 48-53.	3.2	20

#	Article	IF	CITATIONS
37	Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients. Vaccine, 2020, 38, 3339-3350.	3.8	20
38	Mycophenolic Acid Impedes the Antigen Presenting and Lymph Node Homing Capacities of Human Blood Myeloid Dendritic Cells. Transplantation, 2009, 88, 504-513.	1.0	18
39	Response: T cells are required for the CMV-induced antileukemia effect after transplant. Blood, 2012, 119, 1090-1091.	1.4	18
40	Human Cord Blood B Cells Differ from the Adult Counterpart by Conserved Ig Repertoires and Accelerated Response Dynamics. Journal of Immunology, 2021, 206, 2839-2851.	0.8	18
41	Long-Term Response to Vaccination Against Pneumococcal Antigens in Kidney Transplant Recipients. Transplantation, 2012, 94, 50-56.	1.0	17
42	Relationship between pharmacokinetics and pharmacodynamics of calcineurin inhibitors in renal transplant patients. Clinical Transplantation, 2015, 29, 294-300.	1.6	17
43	High negative predictive value of an amplified flow cytometry crossmatch before living donor kidney transplantation. Human Immunology, 2010, 71, 771-776.	2.4	16
44	Potential triggering factors of acute liver failure as a first manifestation of autoimmune hepatitis-a single center experience of 52 adult patients. World Journal of Gastroenterology, 2018, 24, 1410-1418.	3.3	16
45	Cellular in vitro immune function in multiple myeloma patients after high-dose chemotherapy and autologous peripheral stem cell transplantation. Leukemia, 2005, 19, 490-492.	7.2	15
46	Immunity to Pneumococcal Antigens in Kidney Transplant Recipients. Transplantation, 2010, 90, 1463-1467.	1.0	15
47	<i>Ex vivo</i> assessment of cellular immune function–Âapplications in patient care and clinical studies. Tissue Antigens, 2014, 84, 439-449.	1.0	15
48	Convalescent plasma treatment of critically ill intensive care COVID â€19 patients. Transfusion, 2021, 61, 1394-1403.	1.6	15
49	Impact of HLA-A,B,C Allele Mismatches on Outcome after Unrelated Blood Stem Cell Transplantation in Whites. Transplantation, 2004, 78, 1077-1080.	1.0	14
50	Vaccination against Streptococcus pneumoniae does not induce antibodies against HLA or MICA in clinically stable kidney transplant recipients. Human Immunology, 2013, 74, 1267-1270.	2.4	14
51	Impairment of lymphocyte function following yttrium-90 DOTATOC therapy. Cancer Immunology, Immunotherapy, 2015, 64, 755-764.	4.2	14
52	Control of hepatitis B virus infection in hematopoietic stem cell recipients after receiving grafts from vaccinated donors. Bone Marrow Transplantation, 2016, 51, 428-431.	2.4	14
53	Outcome and Genetic Factors in IgG4-Associated Autoimmune Pancreatitis and Cholangitis: A Single Center Experience. Gastroenterology Research and Practice, 2017, 2017, 1-9.	1.5	14
54	Association of the TNFa2 microsatellite allele with the presence of colorectal cancer. Tissue Antigens, 1997, 50, 47-51.	1.0	13

#	Article	IF	CITATIONS
55	The Cytomegalovirus-Specific IL-21 ELISpot Correlates with Allograft Function of Kidney Transplant Recipients. International Journal of Molecular Sciences, 2018, 19, 3945.	4.1	13
56	Adoptive transfer of cellular immunity against cytomegalovirus by virus-specific lymphocytes from a third-party family donor. Bone Marrow Transplantation, 2018, 53, 1351-1355.	2.4	13
57	rhG-CSF effect on mixed lymphocyte cultures and circulating soluble HLA antigen levels in volunteer stem cell donors. Experimental Hematology, 2004, 32, 1103-1109.	0.4	12
58	Detection of Abacavir Hypersensitivity by ELISpot Method. Inflammation and Allergy: Drug Targets, 2012, 11, 227-234.	1.8	12
59	SARSâ€CoVâ€2â€specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma. Journal of Medical Virology, 2021, 93, 3047-3054.	5.0	12
60	SARS-CoV-2 Seroprevalence in Healthcare Workers in Germany: A Follow-Up Study. International Journal of Environmental Research and Public Health, 2021, 18, 4540.	2.6	11
61	COVID-19 in Elderly, Immunocompromised or Diabetic Patients—From Immune Monitoring to Clinical Management in the Hospital. Viruses, 2022, 14, 746.	3.3	11
62	T-cell function after interleukin-2 therapy in HIV-infected patients is correlated with serum cortisol concentrations. Aids, 2004, 18, 2001-2007.	2.2	10
63	Lymphocyte function following radioiodine therapy in patients with thyroid carcinoma. Nuklearmedizin - NuclearMedicine, 2011, 50, 195-203.	0.7	10
64	Lymphocyte function following radium-223 therapy in patients with metastasized, castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 242-246.	6.4	10
65	NKG2Cpos NK Cells Regulate the Expansion of Cytomegalovirus-Specific CD8 T Cells. Journal of Immunology, 2020, 204, 2910-2917.	0.8	10
66	Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis. Neurological Research and Practice, 2021, 3, 60.	2.0	10
67	Low pre-transplant adiponectin multimers are associated with adverse allograft outcomes in kidney transplant recipients a 3-year prospective study. Regulatory Peptides, 2012, 178, 11-15.	1.9	9
68	Vaccination Against Human Papilloma Viruses Leads to a Favorable Cytokine Profile of Specific T Cells. Journal of Immunotherapy, 2016, 39, 316-320.	2.4	9
69	Elevated soluble human leukocyte antigen G levels in patients after allogeneic stem cell transplantation are associated with less severe acute and chronic graft-versus-host disease. Bone Marrow Transplantation, 2018, 53, 1149-1156.	2.4	9
70	Sex-Specific Differences in HLA Antibodies after Pneumococcal Vaccination in Kidney Transplant Recipients. Vaccines, 2019, 7, 84.	4.4	9
71	Long-Term SARS-CoV-2 Specific Immunity Is Affected by the Severity of Initial COVID-19 and Patient Age. Journal of Clinical Medicine, 2021, 10, 4606.	2.4	9
72	In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment. Cancer Immunology, Immunotherapy, 2005, 54, 506-512.	4.2	8

#	Article	IF	CITATIONS
73	Cytomegalovirus induces HLA-class-II-restricted alloreactivity in an acute myeloid leukemia cell line. PLoS ONE, 2018, 13, e0191482.	2.5	8
74	Decreased Soluble Human Leukocyte Antigen E Levels in Patients After Allogeneic Hematopoietic Stem Cell Transplantation Are Associated With Severe Acute and Extended Chronic Graft-versus-Host Disease and Inferior Overall Survival. Frontiers in Immunology, 2019, 10, 3027.	4.8	7
75	Comparison of Three Cellular Assays to Predict the Course of CMV Infection in Liver Transplant Recipients. Vaccines, 2021, 9, 88.	4.4	7
76	Establishment of an ELISpot Assay to Detect Cellular Immunity against S. pneumoniae in Vaccinated Kidney Transplant Recipients. Vaccines, 2021, 9, 1438.	4.4	7
77	Cellular Immune Response after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Vaccines, 2022, 10, 809.	4.4	7
78	Interferon-α Differentially Affects Homeostasis of Human Plasmacytoid and Myeloid Dendritic Cells. Journal of Interferon and Cytokine Research, 2009, 29, 145-160.	1.2	6
79	Therapeutic vaccination of a liver transplant recipient suffering from fulminant hepatitis B during pregnancy. Liver Transplantation, 2013, 19, 1411-1412.	2.4	6
80	Comparison of SARS-CoV-2- and HCoV-Specific T Cell Response Using IFN- \hat{I}^3 ELISpot. Diagnostics, 2021, 11, 1439.	2.6	6
81	Prospective, Longitudinal Study on Specific Cellular Immune Responses after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Kidney Transplant Recipients. Vaccines, 2022, 10, 844.	4.4	6
82	Human leukocyte antigen-DR expression in peripheral blood mononuclear cells from healthy donors influenced by the sera of injured patients prone to severe sepsis. Intensive Care Medicine, 2003, 29, 2285-2290.	8.2	5
83	Altered surface expression patterns of circulating monocytes in cancer patients: impaired capacity of T-cell stimulation?. Cancer Immunology, Immunotherapy, 2004, 53, 1051.	4.2	5
84	Enhancement of Cytomegalovirus-Specific Cytokine Production after Modulation of the Costimulation in Kidney Transplant Patients. Journal of Immunology Research, 2019, 2019, 1-8.	2.2	5
85	Characterization of follicular T helper cells and donor-specific T helper cells in renal transplant patients with de novo donor-specific HLA-antibodies. Clinical Immunology, 2021, 226, 108698.	3.2	5
86	Effect of atorvastatin and clopidogrel on cellular immune function. Prostaglandins Leukotrienes and Essential Fatty Acids, 2003, 68, 251-255.	2.2	4
87	G-CSF-Induced Alteration of In Vitro Alloreactivity in Stem Cell Donors Is Predictive for the Occurrence of Acute GVHD in Recipients. Transplantation, 2005, 79, 377-378.	1.0	4
88	Fetuin-A Pretransplant Serum Levels, Kidney Allograft Function and Rejection Episodes: A 3-Year Posttransplantation Follow-Up. Kidney and Blood Pressure Research, 2011, 34, 328-333.	2.0	4
89	Effect of ABO incompatibility on Tâ€cell flow cytometry crossâ€match results prior to living donor kidney transplantation. Cytometry Part B - Clinical Cytometry, 2018, 94, 623-630.	1.5	4
90	DNA lesions correlate with lymphocyte function after selective internal radiotherapy. Cancer Immunology, Immunotherapy, 2019, 68, 907-915.	4.2	4

#	Article	IF	CITATIONS
91	Species-Specific Interferon-Gamma Release Assay for the Diagnosis of Mycobacterium abscessus Complex Infection. Frontiers in Microbiology, 2021, 12, 692395.	3.5	4
92	Chloroquine Suppresses Effector B-Cell Functions and Has Differential Impact on Regulatory B-Cell Subsets. Frontiers in Immunology, 2022, 13, 818704.	4.8	4
93	Donor cell reaction to OKT3 as predictor of chronic graft-vs-host disease in hematopoietic stem cell recipients. Experimental Hematology, 2006, 34, 1753-1758.	0.4	3
94	Alloreactivity in Recipients Prior to and Post Living Kidney and Liver Transplantation. Scandinavian Journal of Immunology, 2011, 73, 344-345.	2.7	3
95	Donor- and recipient-derived immunity in ABO incompatible living-related liver transplantation. Human Immunology, 2015, 76, 631-635.	2.4	3
96	$\hat{l}\pm\hat{l}^2$ -T-cell depleted donor lymphocyte infusion for leukemia relapse after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2017, 52, 1668-1670.	2.4	3
97	A Single-Nucleotide Polymorphism Upstream of the HLA-C Locus Is Associated With an Anti–Hepatitis C Virus–Seronegative State in a High-Risk Exposed Cohort. Journal of Infectious Diseases, 2018, 218, 2016-2019.	4.0	3
98	Induction of Functional Control in Chronic Hepatitis B Patients with Low Level HBsAg Using a Combination of a PreS1/S2/S HBV Vaccine (Sci-BVacTM) and a Nucleoside Analogue. Journal of Infectious Disease and Therapy, 2019, 07, .	0.1	3
99	Early suppression of peripheral mononuclear blood cells in sepsis in response to stimulation with cytomegalovirus, OKT3, and pokeweed mitogen. Journal of Applied Physiology, 2019, 127, 1539-1547.	2.5	3
100	Pneumococcal Antibodies in Kidney Transplant Recipients are Predictive of Patient Survival. Scandinavian Journal of Immunology, 2013, 78, 554-556.	2.7	2
101	Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN- \hat{l}^3 ELISpot Assay after Hematopoietic Stem Cell Transplantation. Diagnostics, 2021, 11, 312.	2.6	2
102	Cellular and Humoral Immunity after the Third Vaccination against SARS-CoV-2 in Hematopoietic Stem-Cell Transplant Recipients. Vaccines, 2022, 10, 972.	4.4	2
103	Sensitive detection of rare antigen-specific T cells directed against Wilms' tumor 1 by FluoroSpot assay. Leukemia and Lymphoma, 2018, 59, 490-492.	1.3	1
104	SP732INCREASED EXPRESSION OF THE COINHIBITORS PD-1 AND BTLA ON CMV-SPECIFIC T-CELLS IS ASSOCIATED WITH SYMPTOMATIC CMV INFECTION IN RENAL TRANSPLANT PATIENTS. Nephrology Dialysis Transplantation, 2018, 33, i594-i594.	0.7	1
105	Expression pattern of co-inhibitory molecules on CMV-specific T-cells in lung transplant patients. Clinical Immunology, 2019, 208, 108258.	3.2	1
106	Comparison of Humoral and Cellular CMV Immunity in Patients Awaiting Kidney Transplantation. Diagnostics, 2021, 11, 1688.	2.6	1
107	Correlation of Fc Receptor Polymorphisms with Pneumococcal Antibodies in Vaccinated Kidney Transplant Recipients. Vaccines, 2022, 10, 725.	4.4	1
108	EFFECT OF MDR1 AND ABCG8 POLYMORPHISMS ON HEPATITIS C RECURRENCE FOLLOWING LIVER TRANSPLANTATION. Transplantation, 2010, 90, 126.	1.0	0

#	Article	IF	Citations
109	SINGLE NUCLEOTIDE POLYMORPHISMS OF CHEMOKINE RECEPTORS AND ATP-BINDING CASSETTE TRANSPORTER AND RISK OF BILIARY STRICTURES AFTER LIVER TRANSPLANTATION. Transplantation, 2010, 90, 500.	1.0	0
110	HIGH PREDICTIVE VALUE OF A NEGATIVE FLOW CYTOMETRY CROSSMATCH PRIOR TO LIVING DONOR KIDNEY TRANSPLANTATION. Transplantation, 2010, 90, 523.	1.0	0
111	HEPATITIS B SPECIFIC IMMUNE TRANSFER IN ABO INCOMPATIBLE LIVING DONOR LIVER TRANSPLANTATION*. Transplantation, 2010, 90, 856.	1.0	0
112	CLINICAL OUTCOME OF HEPATITIS B VIRUS INFECTION IN PATIENTS RECEIVING HEMATOPOIETIC STEM CELL GRAFTS FROM IMMUNIZED DONORS*. Transplantation, 2010, 90, 1029.	1.0	0
113	Vaccination Antibodies Against Pneumococci and Antibodies Against HLA in Kidney Transplant Recipients. Transplantation, 2012, 94, 847.	1.0	0
114	Soluble Ligands for Activating Natural Killer Receptor (NKG2D) Are Biomarkers for Progression of Hepatic Fibrosis after Liver Transplantation. Transplantation, 2012, 94, 224.	1.0	0
115	Pretransplant C1q Fixing Human Leukocyte Antigen Antibodies and Humoral Rejections in Patients after Living Kidney Transplantation. Transplantation, 2012, 94, 1070.	1.0	0
116	786 INCREASED LEVELS OF SOLUBLE LIGANDS OF THE ACTIVATING NATURAL KILLER RECEPTOR (NKG2D) ARE INDEPENDENT RISK FACTORS FOR ADVANCED FIBROSIS IN LIVER TRANSPLANT RECIPIENTS. Journal of Hepatology, 2012, 56, S308.	3.7	0
117	Determination of nickel and chromium allergy, sensitization, and toxicity by cellular in vitro methods*., 2012,, 322-334.		0
118	721 SOLUBLE LIGANDS FOR ACTIVATING NATURAL KILLER RECEPTOR (NKG2D) AS SCREENING TOOL TO PREDICT SEVERITY OF ALLOGRAFT FIBROSIS AFTER LIVER TRANSPLANTATION. Journal of Hepatology, 2013, 58, S293.	3.7	0
119	160 DONOR SPECIFIC ANTI-MHC CLASS II ANTIBODIES NEGATIVELY IMPACT ALLOGRAFT SURVIVAL FOLLOWING LIVER TRANSPLANTATION. Journal of Hepatology, 2013, 58, S71-S72.	3.7	0
120	Donor Specific Antibodies Against HLA Class II and C4d-Positivity: Risk Factors for Liver Allograft Fibrosis Transplantation, 2014, 98, 161-162.	1.0	0
121	P148 DONOR SPECIFIC ANTIBODIES AGAINST HLA CLASS II AND C4D-POSITIVITY: RISK FACTORS FOR LIVER ALLOGRAFT FIBROSIS. Journal of Hepatology, 2014, 60, S115.	3.7	0
122	The Functional Distance Between Mismatched HLA-DPB1 Increases Risks of Relapse and Mortality after Unrelated Donor Hematopoietic Cell Transplantation for AML, ALL and MDS: A Refinement of the T Cell Epitope Group Algorithm for Permissive Mismatches. Biology of Blood and Marrow Transplantation, 2016, 22, S420-S421.	2.0	0
123	MP315CLINICAL VALIDATION OF A NOVEL ELISPOT-BASED IN VITRO DIAGNOSTIC ASSAY TO MONITOR CMV-SPECIFIC CELL-MEDIATED IMMUNITY IN KIDNEY TRANSPLANT RECIPIENTS. Nephrology Dialysis Transplantation, 2017, 32, iii542-iii542.	0.7	0
124	1575. Clinical Validation of a Novel ELISpot-based in vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in SOT and HSCT Immunocompromised Patients. Open Forum Infectious Diseases, 2018, 5, S491-S492.	0.9	0
125	Clinical Validation of a Novel ELISpot-based in Vitro Diagnostic Assay to Monitor CMV-specific Cell-Mediated Immunity in Kidney Transplant Recipients. Transplantation, 2018, 102, S53.	1.0	0
126	Clinical Validation of a Novel Elispot-Based Diagnostic Assay: Monitoring Cytomegalovirus-Specific Cell-Mediated Immunity and Risk Stratification in Hematopoietic Stem Cell Transplant Recipients. Biology of Blood and Marrow Transplantation, 2019, 25, S342-S343.	2.0	0

#	Article	IF	CITATIONS
127	Therapy-Associated Immunosuppression and Opportunistic Infections in Multiple Myeloma Patients Blood, 2005, 106, 5137-5137.	1.4	O
128	Cytomegalovirus Reduces the Relapse Risk for Acute Leukemia After Transplant: There Is a Virus-Versus-Leukemia Effect Blood, 2009, 114, 2261-2261.	1.4	0
129	Heterogeneous Interactions of Leukemic and Control Bone Marrow Stroma Cells with an AML Cell Line and AML Leukemic Blasts Blood, 2010, 116, 1047-1047.	1.4	O
130	The Functional Distance Between Mismatched HLA-DPB1 Increases Risks of Relapse and Mortality after Unrelated Donor Hematopoietic Cell Transplantation for AML, ALL and MDS: A Refinement of the T Cell Epitope Group Algorithm for Permissive Mismatches. Blood, 2015, 126, 4288-4288.	1.4	0
131	IL-17 ELISpot as Predictor for Kidney Allograft Rejection?. Clinical Laboratory, 2016, 62, 963-5.	0.5	O
132	Correlation of Anti-HLA IgA Alloantibodies and Fc Receptor Motives with Kidney Allograft Survival. Immuno, 2022, 2, 372-386.	1.5	0